You are here

  • Home
  • Archive
  • Volume 15, Issue 4
  • Multi-institutional phase 2 study of TLK286 (TELCYTA™, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer

Article info

Article menu
Download PDFPDF
ORIGINAL ARTICLE
Multi-institutional phase 2 study of TLK286 (TELCYTA™, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer

Authors

  1. Address correspondence and reprint requests to: Gail L. Brown, MD, Telik, Inc., 3165 Porter Drive, Palo Alto, CA 94304, USA. Email: gbrown{at}telik.com

Citation

Kavanagh JJ, Gershenson DM, Choi H, et al
Multi-institutional phase 2 study of TLK286 (TELCYTA™, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer
International Journal of Gynecologic Cancer 2005;15:593-600.

Publication history

  • First published June 1, 2005.
Online issue publication 
June 01, 2005

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Copyright © 2005 Blackwell Publishing Ltd.